News of Note—FDA hires, Ionis bonus and Amgen/Ligand deal

> As the FDA hopes to speed up drug development under its new commissioner Scott Gottlieb, the agency is also looking to find new and speedy ways to fill its employee gap. Gottlieb has put Melanie Keller, currently head of the Office of Management in the Center for Drug Evaluation and Research, in charge of the new recruitment push. FDA Voice post

> Ligand Pharmaceuticals has penned an updated commercial license and supply agreement with Amgen, granting rights to use its technology when making up the formulation of Amgen’s experimental blood cancer med AMG 330. Statement

> Ionis Pharmaceuticals has gained a $10 million biobucks milestone payment from partner Biogen “associated with the validation of an undisclosed neurological disease target.” The pair has long worked together on an R&D collaboration across neurological disorders, including the recently approved SMA med Spinraza (nusinersen). Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.